Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹431.10 Cr
Profit after tax
₹88.12 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations431.10+12.25%1,662.46
Other income28.65−30.29%119.92
Total income459.75+8.14%1,782.38
Employee benefit expense88.91+27.14%313.15
Finance costs4.38+55.82%13.43
Depreciation & amortisation26.47+15.88%97.90
Total expenses341.11+10.72%1,327.69
Profit before tax118.64+1.35%447.89
Tax expense30.52+4.74%111.91
Profit after tax88.12+0.22%335.98
Total comprehensive income87.44+0.45%336.21
Earnings per share
Earnings per share, basic₹8.69₹33.15
Earnings per share, diluted₹8.68₹33.12

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Poly Medicure reported FY26 standalone revenue of around Rs 1,662 crore, up about 4%, and consolidated revenue of Rs 1,875 crore, up 12.3%, with standalone EBITDA margin of 26.8%. Management described FY26 as a year of transition toward high-technology segments, including the acquisitions of PendraCare, Citieffe, and Medyneo in Brazil. The company guided FY27 consolidated revenue of Rs 2,300-2,400 crore and standalone revenue of Rs 1,900-1,950 crore, while flagging raw material cost pressure and Gulf-region shipping disruptions.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 58 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 22 Aug 2026.